AU2001276689A1 - Novel remedies for cancer - Google Patents

Novel remedies for cancer

Info

Publication number
AU2001276689A1
AU2001276689A1 AU2001276689A AU7668901A AU2001276689A1 AU 2001276689 A1 AU2001276689 A1 AU 2001276689A1 AU 2001276689 A AU2001276689 A AU 2001276689A AU 7668901 A AU7668901 A AU 7668901A AU 2001276689 A1 AU2001276689 A1 AU 2001276689A1
Authority
AU
Australia
Prior art keywords
cancer
novel remedies
remedies
novel
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001276689A
Inventor
Akemi Baba
Mitsuharu Hanada
Toshihiro Noguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharmaceuticals Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Publication of AU2001276689A1 publication Critical patent/AU2001276689A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins

Abstract

A medicament for treating cancer for use in combination therapy with an anti-HER2 antibody, which comprises amrubicin or a pharmaceutically acceptable salt thereof as an active ingredient.
AU2001276689A 2000-07-28 2001-07-26 Novel remedies for cancer Abandoned AU2001276689A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-228239 2000-07-28
JP2000228239 2000-07-28
PCT/JP2001/006467 WO2002009754A1 (en) 2000-07-28 2001-07-26 Novel remedies for cancer

Publications (1)

Publication Number Publication Date
AU2001276689A1 true AU2001276689A1 (en) 2002-02-13

Family

ID=18721568

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001276689A Abandoned AU2001276689A1 (en) 2000-07-28 2001-07-26 Novel remedies for cancer

Country Status (13)

Country Link
US (3) US7449181B2 (en)
EP (1) EP1308168B1 (en)
JP (1) JP5117660B2 (en)
KR (1) KR20030019623A (en)
CN (2) CN100581585C (en)
AT (1) ATE397458T1 (en)
AU (1) AU2001276689A1 (en)
CA (1) CA2417255C (en)
DE (1) DE60134324D1 (en)
DK (1) DK1308168T3 (en)
ES (1) ES2307633T3 (en)
TW (1) TWI317285B (en)
WO (1) WO2002009754A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
ES2331646T3 (en) 2000-05-19 2010-01-12 Genentech, Inc. TEST FOR THE DETECTION OF GENES TO IMPROVE THE PROBABILITY OF AN EFFECTIVE ANSWER TO A THERAPY AGAINST CANCER BASED ON ERBB ANTAGONISTS.
DK1488795T3 (en) 2002-03-18 2012-05-07 Dainippon Sumitomo Pharma Co Funds for the treatment of lung cancer
FR2844455B1 (en) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement TREATMENT OF PATHOLOGIES EXCLUDING IMMUNE RESPONSE BY OPTIMIZED ANTIBODIES
WO2006042002A2 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
CN100464783C (en) * 2004-11-22 2009-03-04 山东蓝金生物工程有限公司 Anti-cancer medicine composition containing antineoplastic antibiotics
CN101141981A (en) * 2005-01-21 2008-03-12 健泰科生物技术公司 Fixed dosing of her antibodies
DK1850874T3 (en) 2005-02-23 2013-11-11 Genentech Inc Extension of time to disease progression or survival for ovarian cancer using pertuzumab
WO2006096861A2 (en) * 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
EP2132573B1 (en) 2007-03-02 2014-04-23 Genentech, Inc. Predicting response to a her dimerisation inhbitor based on low her3 expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
PL2171090T3 (en) 2007-06-08 2013-09-30 Genentech Inc Gene expression markers of tumor resistance to her2 inhibitor treatment
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
US8734795B2 (en) 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
TWI461211B (en) 2009-03-20 2014-11-21 Genentech Inc Anti-her antibodies
SG176073A1 (en) 2009-05-29 2011-12-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2744824A1 (en) 2011-08-17 2014-06-25 F.Hoffmann-La Roche Ag Neuregulin antibodies and uses thereof
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
CA2857114A1 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
EP2831115A1 (en) 2012-03-27 2015-02-04 F. Hoffmann-La Roche AG Diagnosis and treatments relating to her3 inhibitors
JP6998646B2 (en) 2012-11-30 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Identification of patients in need of PD-L1 inhibitor combination therapy
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CN107349426B (en) * 2017-07-12 2018-03-23 马骥 Aspirin is combined with Herceptin or cooperates with the application in oncotherapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6075473A (en) * 1983-09-30 1985-04-27 Sumitomo Chem Co Ltd Aminonaphthacene derivative and its preparation
US5185432A (en) * 1986-02-26 1993-02-09 Oncogen Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5077220A (en) * 1988-08-26 1991-12-31 John Muir Cancer & Aging Institute Monoclonal antibody specific to a novel glycoprotein antigen on human carcinoma cells
JPH035397A (en) 1989-05-31 1991-01-11 Toshiba Corp Vapor growth method for thin oxide crystal film
JP3005397B2 (en) 1993-09-06 2000-01-31 関西日本電気ソフトウェア株式会社 Deadlock frequent automatic avoidance method
US5686278A (en) * 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
CN1164238A (en) * 1994-09-12 1997-11-05 国际生物免疫有限公司 Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
AU719434B2 (en) * 1996-02-13 2000-05-11 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
CN1082187C (en) * 1996-11-26 2002-04-03 北京市肿瘤防治研究所 Preparation and use of anti-human estrogen acceptor monoclonal antibody and anti-human progestogen acceptor monoclonal antibody
IL130908A0 (en) * 1997-01-22 2001-01-28 Univ Texas Tissue-factor (tf) compositions for coagulation and tumor treatment
US20030068318A1 (en) * 2001-09-28 2003-04-10 O'brien Timothy Treatment of uterine serous papillary cancer

Also Published As

Publication number Publication date
US7449181B2 (en) 2008-11-11
US20080031881A1 (en) 2008-02-07
ES2307633T3 (en) 2008-12-01
CN101732333A (en) 2010-06-16
US20110104160A1 (en) 2011-05-05
WO2002009754A1 (en) 2002-02-07
EP1308168A4 (en) 2004-09-01
US7879327B2 (en) 2011-02-01
US9139658B2 (en) 2015-09-22
ATE397458T1 (en) 2008-06-15
EP1308168A1 (en) 2003-05-07
CA2417255A1 (en) 2003-01-24
DE60134324D1 (en) 2008-07-17
CA2417255C (en) 2011-08-02
JP5117660B2 (en) 2013-01-16
US20030157097A1 (en) 2003-08-21
EP1308168B1 (en) 2008-06-04
TWI317285B (en) 2009-11-21
CN101732333B (en) 2012-08-15
DK1308168T3 (en) 2008-07-28
CN1466464A (en) 2004-01-07
CN100581585C (en) 2010-01-20
KR20030019623A (en) 2003-03-06

Similar Documents

Publication Publication Date Title
AU2001276689A1 (en) Novel remedies for cancer
AU2001258095A1 (en) Drug delivery systems for photodynamic therapy
AU2001282717A1 (en) Cancer treatment by combination therapy
AU7522601A (en) Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
AU1399492A (en) Remedies for bone diseases
EP1550456A3 (en) Use of botulinum toxin in the treatment of burn pain
AU7031500A (en) Therapeutic quinazoline compounds
PT1196172E (en) (S, S) -REBOXETINE FOR TREATING CHRONIC PAIN
WO2006046080A3 (en) Pegylated liposomal doxorubicin in combination with ecteinescidin 743
WO2002036135A3 (en) Compositions for antitumour treatment containing ecteinascidin 743
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
WO1998008505A8 (en) Pharmaceutical compounds
WO2003041660A3 (en) Solubilized topoisomerase poisons
AU2000272858A1 (en) Pharmaceutical composition for treating hyperhomocysteinaemia caused by medicaments
EP1354896A4 (en) Novel monoclonal antibody
AU2003290015A1 (en) Mastitis treatment
WO2003051289A3 (en) Solubilized topoisomerase poison agents
AU2001243515A1 (en) Combination drug therapy
AU1469097A (en) Pharmaceutical compounds
AU2001258442A1 (en) Drug delivery device, especially for the delivery of levonorgestrel
EE200200605A (en) Use of a Substituted Acryloyldistamycin Derivative in the manufacture of a medicament for the treatment of tumors associated with high levels of glutathione
MY133682A (en) Substituted pyrroles
WO2002066492A3 (en) Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof
WO1997033620A3 (en) Compounds for treating tumours
WO2000048584A3 (en) Aroyl aminoacyl pyrroles for use in the treatment of neuropathic pain